Iteos Therapeutics Other Stockholder Equity Over Time
| ITOS Stock | USD 8.32 0.19 2.34% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Iteos Therapeutics Performance and Iteos Therapeutics Correlation. Iteos |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Iteos Therapeutics. If investors know Iteos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Iteos Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.89) | Earnings Share (3.14) | Revenue Per Share 0.906 | Quarterly Revenue Growth (1.00) | Return On Assets (0.13) |
The market value of Iteos Therapeutics is measured differently than its book value, which is the value of Iteos that is recorded on the company's balance sheet. Investors also form their own opinion of Iteos Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Iteos Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Iteos Therapeutics' market value can be influenced by many factors that don't directly affect Iteos Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Iteos Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Iteos Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Iteos Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Other Stockholder Equity Analysis
Compare Iteos Therapeutics and related stocks such as Icosavax, Mirati Ther, and VectivBio Holding Other Stockholder Equity Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ANNX | (26 K) | (26 K) | (26 K) | (26 K) | (26 K) | (26 K) | (26 K) | (26 K) | 1.3 M | 2.2 M | 154.4 M | 528.4 M | 669.8 M | 823 M | 864.2 M |
| GLUE | 50 K | 50 K | 50 K | 50 K | 50 K | 50 K | 50 K | 50 K | 50 K | 50 K | 404 K | 471.6 M | 503.7 M | 547.9 M | 335.2 M |
| DSGN | (44.9 M) | (44.9 M) | (44.9 M) | (44.9 M) | (44.9 M) | (44.9 M) | (44.9 M) | (44.9 M) | (44.9 M) | (44.9 M) | (44.9 M) | 429.8 M | 441.4 M | 455.2 M | 352.4 M |
| ERAS | (63.3 M) | (63.3 M) | (63.3 M) | (63.3 M) | (63.3 M) | (63.3 M) | (63.3 M) | (63.3 M) | (63.3 M) | (63.3 M) | (220 M) | 193.4 M | 893.9 M | 922.6 M | 968.7 M |
| APLS | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 2 M | 28.9 M | 30 M | 298.2 M | 437.9 M | 615.8 M | 1.1 B | 1.9 B | 2.5 B | 3 B | 3.2 B |
| TCRX | (59.4 M) | (59.4 M) | (59.4 M) | (59.4 M) | (59.4 M) | (59.4 M) | (59.4 M) | (59.4 M) | (59.4 M) | (59.4 M) | 1.1 M | 441 M | 257.8 M | 398.5 M | 228.6 M |
| TERN | 455 K | 455 K | 455 K | 455 K | 455 K | 455 K | 455 K | 455 K | 455 K | 1.2 M | 14.6 M | 342.7 M | 520.2 M | 588 M | 617.4 M |
| DAWN | (5.4 M) | (5.4 M) | (5.4 M) | (5.4 M) | (5.4 M) | (5.4 M) | (5.4 M) | (5.4 M) | (5.4 M) | (5.4 M) | 92.6 M | 408.6 M | 601.8 M | 805.1 M | 418.6 M |
| ABOS | (9.2 M) | (9.2 M) | (9.2 M) | (9.2 M) | (9.2 M) | (9.2 M) | (9.2 M) | (9.2 M) | (9.2 M) | (9.2 M) | 65 M | 353 M | 359.9 M | 489.5 M | 276.8 M |
| MLTX | 42.1 M | 42.1 M | 42.1 M | 42.1 M | 42.1 M | 42.1 M | 42.1 M | 42.1 M | 42.1 M | 42.1 M | 42.1 M | 42.1 M | 129.2 M | 610 M | 640.5 M |
| RVMD | 2.4 M | 2.4 M | 2.4 M | 2.4 M | 2.4 M | 2.4 M | 2.4 M | 2.4 M | 210 M | 4.7 M | 740.1 M | 1.1 B | 1.4 B | 3 B | 3.1 B |
| BPMC | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 4.4 M | 102.1 M | 420.5 M | 979.8 M | 1 B | 1.4 B | 2.1 B | 2.3 B | 2.4 B | 2.5 B | 1.3 B |
| SANA | 59 K | 59 K | 59 K | 59 K | 59 K | 59 K | 59 K | 59 K | 59 K | (415.8 M) | 852.9 M | 1.5 B | 1.6 B | 1.6 B | 941.7 M |
| KYMR | 774 K | 774 K | 774 K | 774 K | 774 K | 774 K | 774 K | 774 K | 774 K | (107 M) | 412.8 M | 689.3 M | 878.9 M | 926.3 M | 513.5 M |
Iteos Therapeutics and related stocks such as Icosavax, Mirati Ther, and VectivBio Holding Other Stockholder Equity description
My Equities
My Current Equities and Potential Positions
| Iteos Therapeutics | ITOS |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Massachusetts; U.S.A |
| Exchange | NASDAQ Exchange |
USD 8.32
Additional Tools for Iteos Stock Analysis
When running Iteos Therapeutics' price analysis, check to measure Iteos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Iteos Therapeutics is operating at the current time. Most of Iteos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Iteos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Iteos Therapeutics' price. Additionally, you may evaluate how the addition of Iteos Therapeutics to your portfolios can decrease your overall portfolio volatility.